Mastering the Classics With Dr Gillman: Unlocking the Potential of MAOIs and TCAs in Modern Psychiatry

academy backgroundipadmock up image copy

Downloadable PDFs Downloadable PDFs

Download Certificates Download Certificates

Welcome to the on-demand webinar episode with Dr Ken Gillman – Mastering the Classics: Unlocking the Potential of MAOIs and TCAs in Modern Psychiatry.

This online course is designed to broaden your understanding of the clinical application of MAOIs and TCAs in modern psychiatry practice. This comprehensive program offers an exceptional opportunity to gain invaluable insights into the utilization of these vital therapeutic alternatives within the realm of Major Depressive Disorder management.

While newer antidepressant medications may have gained popularity over the years, TCAs and MAOIs remain a vital part of psychiatric care. Members will benefit from a comprehensive overview of the subject, with topics covered including identifying patients suitable for TCAs, how MAOIs work in comparison to other medications, and absolute and relative contraindications for their use.

Other key areas to be explored include when to initiate TCA and MAOI treatment, effective management of side effects, and augmentation options for patients taking MAOIs.

Topics covered include:

  • Developing an understanding of the clinical application of MAOIs and TCAs in modern psychiatry practice.
  • Identifying patients who are good candidates for TCAs and gaining insights into when to introduce these medications
  • Comparing the mechanism of action of MAOIs to SSRI, SNRI and TCAs
  • Gaining knowledge of the different types of MAOIs and when to use them in the management of depression
  • Recognising absolute and relative contraindications for the use of MAOIs and TCAs
  • Learning effective strategies for initiating treatment with MAOIs and managing their side effects
  • Understand the augmentation options available for patients taking MAOIs

Speaker profile – Dr Ken Gillman

Dr Ken Gillman is a world-renowned researcher and authority in the field of psychiatry, with a focus on serotonin toxicity, monoamine oxidase inhibitor (MAOI) antidepressant drugs, and related topics. He is currently the Principal Investigator and Director at PsychoTropical Research, where he leads a team of experts who publish papers in his areas of specialization in the peer-reviewed scientific literature.

Dr Gillman’s research contributions have earned him an impressive H-index of 29 and a cumulative total of more than 4,500 citations. He has authored approximately fifteen major single-author review papers that have been extensively cited (between 100-500 times).

As the founder and convener of the International MAOI Expert Group and the Chairman of its presiding council, Dr. Gillman has played a pivotal role in advancing the understanding and clinical application of MAOIs in psychiatry. He is also an invited expert participant in the Malignant Hyperthermia Association of the US (MHAUS) expert group.

With his vast expertise and groundbreaking research contributions, Dr Gillman is highly regarded as a thought leader and innovator in the field of psychiatry. His insights and perspectives are sure to enrich any discussion and deepen our understanding of the clinical application of MAOIs and TCAs in modern psychiatry practice.

Dr Sanil Rege is a Consultant psychiatrist and academic with dual qualifications from the UK and Australia. He is a Fellow of the Royal Australian and New Zealand College of Psychiatrists and a Member of the Royal College of Psychiatrists (UK).

Get Started